Effects of rufloxacin in Salmonella typhimurium infection in mice.
This study was undertaken to investigate the efficacy of rufloxacin, a new quinolone which is interesting due to its pharmacokinetics characterized by a long plasma half-life, in the treatment of systemic salmonella infections in the mouse typhoid model. Innately susceptible BALB/c and resistant CBA mice were used to investigate the efficacy of rufloxacin in controlling systemic salmonella infections when given for brief or prolonged periods. The present study shows that rufloxacin is not only very effective on both mouse strains, but can completely eradicate the salmonellae from livers and spleens when given early in the infection of CBA resistant mice.
Bonina
L
L
Microbiology Institute, Medical School, Messina University, Italy.
Carbone
M
M
Mastroeni
P
P
Costa
G B
GB
Mastroeni
P
P
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004198:Disease Susceptibility; D005260:Female; D024841:Fluoroquinolones; D007113:Immunity, Innate; D008099:Liver / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D015363:Quinolones / Q000627:therapeutic use*; D012481:Salmonella Infections, Animal / Q000188:drug therapy* / Q000276:immunology; D012486:Salmonella typhimurium / Q000187:drug effects / Q000254:growth & development; D013154:Spleen / Q000382:microbiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C060328:rufloxacin